Where Are Peptides Made? From the Body to the Factory Floor

Published September 2026 · Patriot Labs Research Team · ~25 min read

The short answer

Peptides are made in two kinds of place: inside living cells, where ribosomes build them from genetic instructions, and in chemical and biotech plants, where they are synthesized or fermented to order. Commercially, most of the world’s peptide supply is manufactured in a small number of specialist plants in the United States, Europe, China and India.

In the biological sense, peptides come from genes. A cell copies a gene into messenger RNA, a ribosome reads that message and links amino acids into a chain, and many of those chains are then trimmed out of larger precursor proteins by processing enzymes. Insulin, oxytocin and glucagon are all made this way in the body. Microbes also make peptides by a second route that does not use the ribosome at all, and digestion releases peptide fragments from the proteins in food.

The rest of this guide takes both meanings in turn: where peptides come from in nature, the three ways people have learned to make them, where the industry physically sits and why, and what a label like “made in USA” can and cannot tell a buyer about a research vial. The chemistry of how a peptide is assembled, purified and freeze-dried is covered in depth in the companion guide, How Peptides Are Made; this page is about where.

Where peptides come from in nature

Nature makes peptides in four main ways: on the ribosome, by cutting larger precursor proteins, on dedicated enzyme assembly lines in microbes, and by breaking down dietary protein. The first two account for the peptide hormones and signalling molecules of animals; the third for many antibiotics and toxins; the fourth for the short fragments released during digestion.

The ribosome: every gene-encoded peptide starts here

A peptide is a short chain of amino acids joined by amide (peptide) bonds — chemically the same thing as a protein, just shorter. Every peptide encoded in a genome begins the same way. The cell transcribes the gene into messenger RNA; the mRNA reaches a ribosome; the ribosome reads it three bases at a time and adds the matching amino acid to a growing chain. For peptides destined to leave the cell, that happens on ribosomes bound to the rough endoplasmic reticulum, which feeds the new chain into the secretory pathway. So the most literal answer to “where are peptides made in the body” is: at the ribosome, in essentially every cell type, with hormone-secreting tissue such as the pancreas, the pituitary and the gut lining doing a great deal of it.

Prohormones: most signalling peptides are cut out of something bigger

The ribosome rarely produces a finished hormone directly. Far more often it makes a longer, inactive precursor — a prohormone — and specialised enzymes called prohormone convertases cut the active peptide out of it inside secretory granules, typically at pairs of basic amino acids. Further enzymes then trim the ends, and some peptides are finished with a C-terminal amide or other modification before release.

Insulin is the textbook example. It is synthesised as a single chain, proinsulin, which folds and forms its disulfide bridges before being cleaved to release insulin and a connecting fragment, C-peptide. Work on human islet cells published in 2020 found that human β-cells carry out that processing with prohormone convertase 1/3 rather than, as long assumed, a combination of PC1/3 and PC2.^[1] Pro-opiomelanocortin (POMC) is the other classic case: one precursor protein that different tissues cut in different places, which is how the same gene can give rise to several distinct peptide hormones depending on where it is expressed. The practical lesson for anyone thinking about sourcing is that biology’s peptide “factory” is a two-stage process — build a long chain, then cut it — and that the second stage is as important as the first.

Non-ribosomal peptides: microbes’ assembly lines

Bacteria and fungi have a second, completely independent way to make peptides. Very large multi-domain enzymes called non-ribosomal peptide synthetases (NRPS) act as molecular assembly lines: each module selects one building block, activates it and passes the growing chain to the next module. Because no ribosome and no genetic code is involved, these peptides can include building blocks the ribosome cannot use — D-amino acids, unusual side chains, rings and fatty-acid tails. A 2017 review of the field counts more than 20 marketed drugs that originate from this pathway, including the antibiotics penicillin and vancomycin.^[2] It is a useful reminder that “natural” and “made only of the twenty standard amino acids” are not the same thing.

Digestion: peptides released from food protein

A fourth source is breakdown rather than synthesis. When dietary proteins such as milk casein or whey are digested — or fermented, or deliberately hydrolysed in food processing — enzymes cut them into shorter fragments, some of which are peptides with measurable activity in laboratory assays. The field that studies these “food-derived bioactive peptides” is large, and the fragments are real, but activity in a laboratory assay does not by itself establish any effect outside the test tube. From a sourcing point of view, these peptides are made in the gut or in a food-processing vessel, not in a synthesis plant.

Venoms and toxins: a historical source of leads

Venomous animals — snakes, cone snails, spiders, scorpions, lizards — have evolved peptide toxins that act with extraordinary potency on specific receptors and ion channels, and pharmacologists have mined them for leads for decades. Exendin-4, the natural peptide behind the GLP-1 receptor agonist exenatide, is a 39-amino-acid peptide first isolated in 1992 from the venom of the Gila monster.^[3] In every such case the animal is only the source of the idea: the commercial molecule is made in a factory, by synthesis or fermentation, not harvested from the animal.

Three ways humans make peptides

People have obtained peptides in three ways, in roughly historical order: by extracting them from animal tissue, by programming microorganisms to express them, and by building them chemically. Extraction is now largely obsolete; recombinant expression and chemical synthesis supply essentially everything made today, and the choice between them decides what kind of plant a peptide comes from.

Extraction from tissue. The first peptide to change medicine, insulin, was obtained by extracting it from animal pancreas. The 1923 Nobel Prize in Physiology or Medicine went to Frederick Banting and John Macleod “for the discovery of insulin,”^[4] and for decades afterward the world’s insulin supply came from the pancreases of cattle and pigs collected at slaughterhouses. In that era the answer to “where are peptides made” was, quite literally, in the meatpacking industry. Supply was tied to livestock throughput, and the product was the animal’s sequence rather than the human one.

Recombinant expression. From the late 1970s, genetic engineering allowed a synthetic gene to be placed into a microorganism such as Escherichia coli or yeast, which then expresses the peptide or a precursor in a fermenter. A 1979 paper reported the expression in E. coli of chemically synthesised genes for human insulin,^[5] and when the FDA licensed recombinant human insulin — developed by Genentech and licensed to Eli Lilly — in October 1982, it became the first recombinant pharmaceutical approved for use in the United States.^[6] Recombinant plants look like breweries: fermenters, harvest and purification trains, and the biological quality controls that come with living cells.

Chemical synthesis. In 1963 R. B. Merrifield published solid-phase peptide synthesis (SPPS), in which the chain is built one protected amino acid at a time on an insoluble resin bead.^[7] SPPS, together with older solution-phase methods (LPPS) and hybrids of the two, is how the great majority of short and modified peptides are made, and it is the route behind almost all research-catalogue peptides. A synthesis plant looks like a chemical plant: large stirred reactors, solvent tanks, preparative chromatography columns and freeze-dryers. The step-by-step chemistry of both industrial routes, including why chain length and non-natural residues push a molecule toward one or the other, is set out in How Peptides Are Made.

The route matters for the geography question because the two kinds of plant are built by different companies with different skills. Recombinant capacity sits mostly with large biopharmaceutical manufacturers. Synthetic capacity sits with a mixture of drug companies and specialist contract manufacturers — and, at the research end, with a long tail of custom-synthesis laboratories.

Where the world’s pharmaceutical peptides are made

Regulated, pharmaceutical-grade peptide ingredient is made in a concentrated set of plants in the United States, Switzerland and wider Europe, China and India, operated partly by drug companies themselves and partly by specialist contract development and manufacturing organisations (CDMOs). The companies below are named because their sites could be verified from their own published material for this guide; they are examples, not a complete list.

For context on pharmaceutical ingredients in general, not peptides specifically: in 2019 testimony to Congress, the director of the FDA’s drug centre reported that, as of August 2019, 28% of the facilities making active pharmaceutical ingredients (APIs) for the US market were in the United States, 26% in the European Union, 18% in India, 13% in China, 2% in Canada and 13% in the rest of the world, and that the number of registered API facilities in China had more than doubled between 2010 and 2019.^[8] Those are counts of facilities, not volumes, and they cover every kind of drug; but they give a fair picture of where regulated API manufacturing sits.

Switzerland and the rest of Europe

Switzerland is home to several of the longest-established contract peptide manufacturers. Bachem, founded in 1971, lists sites at Bubendorf, Vionnaz and Sisslerfeld in Switzerland, at Torrance and Vista in the United States, and at St. Helens in the United Kingdom.^[9] CordenPharma announced in March 2025 a greenfield peptide plant of more than €500 million at Muttenz, in the Basel region, with more than 5,000 litres of SPPS reactor capacity and commercial operations planned from the first half of 2028, as part of a stated programme of more than €1 billion across its European and US peptide sites.^[10] PolyPeptide, a peptide-focused CDMO, lists manufacturing at Malmö (Sweden), Braine-l’Alleud (Belgium) and Strasbourg (France), alongside sites in the US and India.^[11]

The United States

US peptide API capacity is a mix of contract manufacturers and, increasingly, drug companies’ own plants. CordenPharma’s Colorado site operates a 10,000-litre SPPS reactor that the company described in 2023 as part of the largest SPPS manufacturing facility worldwide, with more than two metric tons of annual peptide capacity;^[12] in 2025 it said it planned to add 25,000 litres there to reach more than 42,000 litres of SPPS capacity by 2028.^[10] Bachem (Torrance and Vista, California) and PolyPeptide (Torrance and San Diego) both operate US sites.^[9][11] AmbioPharm, headquartered in North Augusta, South Carolina, makes peptide APIs at facilities in South Carolina and Shanghai.^[13] The largest recent additions are the drug makers’ own API plants, covered in the GLP-1 section below.

China

China hosts some of the largest peptide synthesis operations in the world. WuXi AppTec reported in January 2024 that it had tripled its SPPS reactor volume to 32,000 litres across its Changzhou facility and a new site at Taixing,^[14] and in March 2026 that it had completed further peptide capacity construction in September 2025, taking total solid-phase synthesizer reactor volume above 100,000 litres, with revenue in the unit that handles peptides and oligonucleotides up 96% year on year.^[15] Hybio Pharmaceutical, a peptide specialist, announced in January 2026 that its Wuhan subsidiary had completed Chinese regulatory registration of a semaglutide API.^[16] Chinese sites supply regulated markets as well as the domestic one; a plant’s nationality says little on its own about which quality system it operates under.

India

India is a large generic-drug producer that is now building peptide capability quickly. PolyPeptide announced in October 2025 that it was expanding its Ambernath facility to more than three times its production capacity.^[17] When semaglutide’s patent protection ended in India on 20 March 2026, a long list of Indian drug makers — including Sun Pharma, Dr. Reddy’s, Cipla, Biocon, Lupin, Zydus and others — moved to launch generic versions.^[18] Launching a finished product is not the same as making its API, and those announcements do not all say where the peptide ingredient itself is synthesised, which is exactly the distinction the rest of this guide keeps returning to.

Where research-grade peptides come from

Research-grade and catalogue peptides are made in a much wider and less visible set of places than pharmaceutical API, and a large share of that synthesis is widely reported to take place in China. There is no public registry that records where a given research peptide was synthesised, so no one can give a reliable market-share figure; what can be said is where the capacity is and what the trade data and published studies show.

Research-grade peptides are small in mass — milligrams to grams — and highly varied in sequence, so they are made by custom-synthesis laboratories running banks of automated synthesizers rather than by the very large reactors of API plants. That work happens in the United States and Europe, where university core facilities and commercial custom-synthesis companies operate, and at much larger volume in China. The layout of a single company can span both: GenScript, whose US operations are headquartered in Piscataway, New Jersey, described a 2023 expansion of its peptide and oligonucleotide plant in Zhenjiang, China, as capable of up to 30,000 peptides a month for research and preclinical customers.^[20] AmbioPharm similarly runs synthesis in both South Carolina and Shanghai.^[13] A US address on the company, in other words, is not a statement about where a specific lot was synthesised.

Trade data points the same way, with caveats. The New York Times, citing US customs data, reported that imports of hormone and peptide compounds from China roughly doubled from $164 million in the first three quarters of 2024 to $328 million in the same period of 2025.^[21] That category is broad — hormone classifications in the tariff schedule, such as heading 2937, also cover insulin, somatotropin and steroidal hormones used in ordinary pharmaceutical trade^[22] — so the figure is a signal of direction, not a measure of the research-peptide market.

Peer-reviewed work on the online market also documents the pattern. A 2025 study of the international online supply of semaglutide and related compounds found thousands of listings from China-based sellers on a single business-to-business platform, many carrying “for research use only” wording alongside marketing that contradicted it.^[23] The authors’ concern centred on how easily such platforms let inexperienced buyers obtain products that may be contaminated or misrepresented. For a buyer, the useful point is this: a plant anywhere can make a clean peptide or a poor one, and the difference shows up in testing and paperwork, not in the flag on the address.

Why the map looks like this

Peptide manufacturing clusters where three things are already present: deep chemical-manufacturing capacity, a local supply of the specialised raw materials, and regulatory systems that the target markets accept. Each region on the map has a different mix of those three.

Chemistry capacity and skilled labour. SPPS is solvent- and reagent-intensive chemistry run at scale, followed by preparative chromatography and freeze-drying. It fits naturally into regions that already have fine-chemical and API industries, trained process chemists and the permits to handle large solvent volumes. Switzerland’s Basel region and the fine-chemical clusters of eastern China are examples of places where that ecosystem existed before peptides became a large business.

Raw materials. The inputs — protected amino acids, resins, coupling reagents and very large quantities of solvent — are themselves chemical products, and making peptides close to where they are produced reduces cost and lead time. This is the main reason research-grade synthesis is cheapest where the upstream chemical industry is largest. The cost structure of synthesis, including why solvent and purification dominate it, is covered in How Peptides Are Made.

Regulation and market access. A plant that wants to supply API for an approved drug must operate to Good Manufacturing Practice (GMP) — for APIs, the ICH Q7 framework — and accept inspection by the regulators of the markets it sells into.^[24] That requirement concentrates regulated production in sites with long inspection histories, whichever country they are in. Research-grade material carries no such requirement, which is why it can be made in a far wider range of facilities, and why its quality varies more widely.

Policy. Governments now regard pharmaceutical supply chains as a strategic matter. In September 2025 the FDA created a “green list” import alert for GLP-1 APIs: it lists ingredients from facilities the agency has inspected or evaluated that appear to be in compliance with its standards, and APIs from other sources are subject to detention without physical examination.^[25] The same pressure lies behind the large US plant announcements described next.

The GLP-1 build-out: where new capacity is going

Demand for GLP-1 receptor agonist medicines has set off the largest expansion of peptide manufacturing capacity on record, and most of the newly announced API capacity is in the United States, Switzerland and China. The figures below are the companies’ own announcements; they describe investments in capacity for approved and pipeline drugs, and they say nothing about research-grade material.

Drug makers building their own API plants. Eli Lilly said in May 2024 that its investment in a new site in Lebanon, Indiana, would rise by $5.3 billion to $9 billion, to make API for tirzepatide and pipeline medicines, with production beginning toward the end of 2026 and scaling through 2028; the company called it the largest investment in synthetic medicine API manufacturing in US history.^[19] It followed with a $6.5 billion API plant in Houston, Texas, announced in September 2025 for small-molecule medicines including its oral GLP-1 candidate,^[26] and a $6 billion facility in Huntsville, Alabama, announced in December 2025 to make small-molecule and peptide APIs, with construction beginning in 2026 and completion expected in 2032.^[27]

Fill-finish by acquisition. Synthesising a peptide is only half the job; the finished drug has to be filled into sterile containers. In December 2024 Novo Holdings completed its roughly $16.5 billion acquisition of the contract manufacturer Catalent, under a deal in which three Catalent fill-finish sites — in Anagni (Italy), Bloomington (Indiana) and Brussels (Belgium) — were to be sold on to Novo Nordisk.^[28] That a single product line can draw on filling plants in three countries is a concrete illustration of how the steps of peptide manufacturing are distributed.

Contract manufacturers. CordenPharma’s Swiss greenfield plant and Colorado expansion,^[10] WuXi AppTec’s growth past 100,000 litres of SPPS reactor volume,^[15] and PolyPeptide’s tripling of its Indian site^[17] are all part of the same response. Capacity of this kind takes years to plan, build and qualify, which is why several of these plants are not expected to reach full operation until 2028 or later.

The journey of one research vial

A single research vial usually passes through several distinct steps — synthesis, purification, freeze-drying, filling, labelling, testing and distribution — and those steps are often done by different organisations, sometimes in different countries. “Where was this peptide made?” therefore has several correct answers at once, one for each step.

Synthesis. The peptide chain is assembled, cleaved from the resin and precipitated as a crude solid. For research material this is typically done by a custom-synthesis laboratory or a peptide manufacturer, and it is the step most often meant by “made in.”

Purification and salt form. The crude peptide is purified, usually by preparative reversed-phase HPLC, and ends up as a particular salt (commonly trifluoroacetate or acetate — see TFA vs acetate). This is normally done by the same organisation that synthesised it.

Lyophilisation. The purified solution is freeze-dried to a stable powder. Bulk powder can be shipped in this form and divided later.

Fill and finish. The powder, or a solution of it, is dispensed into individual vials, freeze-dried in the vial if needed, stoppered and sealed. This may be done by the synthesis plant, by a separate filling operation, or by the brand that sells the vial.

Labelling and batching. The vial receives a label and lot number. The lot number is the thread that ties every later document to the physical material.

Testing. Samples from the lot are tested for identity and purity, typically by HPLC and mass spectrometry. The manufacturer may test; the seller may commission an independent laboratory; ideally both. What those tests do and do not show is covered in Understanding Peptide COA Testing.

Storage and distribution. The seller stores the stock and ships it. Temperature history during this stage matters to the integrity of the material, as the guides on storage and cold-chain handling explain.

The practical consequence is that the documents, not the marketing, carry the information. A certificate of analysis that names the lot, the method and the laboratory that ran the test tells a buyer something verifiable about the material in the vial. A country name without documentation tells them very little. That is also why a seller can be honest about testing without being able to say where synthesis happened: they may know the first fact directly and the second only from a supplier’s paperwork.

What “made in USA” can and cannot mean for a peptide

For a peptide, “made in USA” can refer to any of several different steps — synthesis, filling, testing or simply the seller’s location — and unless the claim says which, it is ambiguous. The strictest reading, the one US consumer-protection law applies to labels, requires that essentially the whole product and its significant processing be domestic.

The Federal Trade Commission’s Made in USA Labeling Rule reads an unqualified “made in the United States” claim on a label as requiring three things together: final assembly or processing in the United States, all significant processing in the United States, and all or virtually all ingredients or components made and sourced in the United States.^[29] Applied to a peptide, the synthesis of the peptide itself would plainly count as significant processing. A vial filled in the United States from peptide synthesised elsewhere would not, on that reading, meet the unqualified standard; accurate qualified wording — “filled in the USA,” “tested in the USA,” “US-based company” — describes something narrower and different.

None of those narrower statements is a bad thing. Domestic filling, domestic independent testing and a domestic company to hold accountable are all meaningful. The point is only that they answer different questions, and a buyer is entitled to know which question is being answered. Four distinctions are worth keeping separate:

• Where the peptide was synthesised — the chemistry step. This is what “made in” most naturally means, and it is the fact least often documented to the end buyer in the research market.
• Where it was filled and labelled — the step that turns bulk powder into individual vials.
• Where it was tested, and by whom — the step that produces the certificate of analysis. An independent laboratory named on the COA is a checkable fact.
• Where the seller is based — which determines jurisdiction and accountability, but says nothing on its own about the material.

Useful questions, asked neutrally, follow directly: Which of those steps happened in the United States? Is the certificate of analysis specific to the lot number printed on the vial? Does it name the laboratory that ran the test, and is that laboratory independent of the seller and the manufacturer? Does it report both purity (HPLC) and identity (mass spectrometry)? A supplier who cannot answer the synthesis question may still be able to answer all of the testing questions precisely, and those answers are the ones that can be verified. For a fuller checklist, see How to Buy Research Peptides.

For reference: Patriot Labs is a first-responder-owned, US-based company. Every batch it sells is tested by an independent US laboratory by HPLC and mass spectrometry, and the certificate of analysis is published on the product page — the same documents this section recommends asking any vendor for.

Research grade vs GMP: two different systems

The same peptide sequence can be made to two very different standards. GMP-grade API is made under a regulated, inspected quality system for use in approved medicines; research-grade material is made to the supplier’s own specification for laboratory use, and the phrase “research grade” is not a regulatory standard at all.

GMP for APIs, as set out in ICH Q7 and adopted by the FDA as guidance, calls for a quality unit independent of production, complete batch production records for every batch, documented process validation, and reserve samples of each batch retained after release — a system that regulators inspect.^[24] The FDA’s GLP-1 green list is an example of that system at work: it ties how a shipment of a particular API is handled at the border to the inspection status of the facility that made it.^[25]

Research-grade manufacture has none of those obligations by default, and its buyers are laboratories rather than drug makers. That does not make research material poor — the same chemistry and the same instruments are used, and many research peptides are very pure — but it does mean that quality has to be demonstrated lot by lot rather than inferred from the system that made it. This is why independent testing and a lot-specific certificate of analysis matter so much more in the research market than in the regulated one. It also means research-grade material should never be described or handled as the approved drug that shares its sequence: a research compound with the same name as an approved medicine is not that medicine, has not been made under the same controls and is not sold for the same purpose. A fuller comparison of the two grades appears in How Peptides Are Made, and the regulatory distinction between a peptide, a drug and a biologic is covered in Peptide vs Drug vs Biologic.

What this guide does not establish

This guide describes where the peptide industry is, not where any particular vial came from, and several of its conclusions rest on incomplete public information.

• There is no public registry of research-peptide origin. Regulators track facilities that make approved-drug ingredients; nobody publishes an equivalent record for research-grade synthesis. Statements about China’s share of research-grade synthesis rest on capacity announcements, trade data and market studies, not on a census.
• Trade figures are proxies. Customs categories group peptides with other hormones and pharmaceutical materials, so import values indicate direction, not the size of the research market.^[21][22]
• Capacity figures are company statements. Reactor volumes, investment amounts and timelines are as announced by the companies; plans change, and announced capacity is not the same as output.
• The company list is illustrative. Many capable peptide manufacturers are not named here simply because their sites were not verified for this guide.
• Nothing here describes Patriot Labs’ own supply chain beyond the testing facts stated above.
• Nothing here describes any use in a person or animal. Biology is described to explain where peptides come from, not what any compound does.

Frequently asked questions

Where are peptides made?

Peptides are made in two kinds of place: inside living cells, where ribosomes build them from genetic instructions, and in chemical and biotech plants, where they are synthesized or fermented to order. Commercially, most of the world’s peptide supply is manufactured in a small number of specialist plants in the United States, Europe (especially Switzerland), China and India, run by drug companies and contract manufacturers.

Where do peptides come from?

Biologically, peptides come from genes: a ribosome reads messenger RNA and links amino acids into a chain, and many peptide hormones are then cut out of longer precursor proteins by processing enzymes. Microbes also make peptides on enzyme assembly lines that bypass the ribosome, and digestion releases peptide fragments from food protein. Commercially, peptides come from chemical synthesis plants or from fermenters running engineered microorganisms.

Are peptides natural or synthetic?

Both. Many peptides occur naturally, including hormones such as insulin, oxytocin and glucagon. The peptides sold for research and used in medicine today are almost all manufactured, either by chemical synthesis or by recombinant expression in microorganisms, even when their sequence is identical to a natural one. Some manufactured peptides are deliberately modified with non-natural building blocks that do not occur in nature.

Are most research peptides made in China?

A large share of research-grade peptide synthesis is widely reported to take place in China, which has very large peptide synthesis capacity and a deep supply of the chemical raw materials involved. There is no public registry of where research peptides are synthesized, so no reliable market-share figure exists. Country of synthesis also says little about quality on its own; lot-specific testing and documentation are what distinguish one batch from another.

What does ‘made in USA’ mean for a peptide?

It can refer to different steps: where the peptide was synthesized, where it was filled into vials, where it was tested, or where the selling company is based. Under the FTC’s labeling rule, an unqualified ‘Made in USA’ claim on a label requires final processing, all significant processing and all or virtually all components to be domestic, and synthesis of the peptide would count as significant processing. Narrower wording such as ‘tested in the USA’ describes a different, specific fact.

How are peptides made?

Industrially, by chemical synthesis or by recombinant expression. Chemical synthesis, usually solid-phase peptide synthesis, builds the chain one protected amino acid at a time on a resin, followed by cleavage, HPLC purification and freeze-drying. Recombinant expression places a synthetic gene into a microorganism grown in a fermenter. The full process is explained in the companion guide How Peptides Are Made.

Where is insulin made in the body?

In the beta cells of the pancreatic islets. The cell first makes a single-chain precursor, proinsulin, which folds and forms disulfide bridges before processing enzymes cut it into insulin and a connecting fragment called C-peptide. Commercially, insulin was first extracted from animal pancreas and has for decades been produced by recombinant microorganisms.

Who are the largest peptide manufacturers?

Regulated peptide ingredient is made both by drug companies in their own plants and by specialist contract manufacturers. Contract manufacturers with large peptide operations include Bachem and CordenPharma in Switzerland and the United States, PolyPeptide in Europe, the United States and India, and WuXi AppTec in China, which reported more than 100,000 litres of solid-phase synthesis reactor volume in 2026. Rankings change quickly as new plants are built.

Is research-grade peptide the same as pharmaceutical-grade?

No. Pharmaceutical (GMP) peptide ingredient is made under a regulated, inspected quality system for use in approved medicines. Research-grade material is made to the supplier’s own specification for laboratory use, and ‘research grade’ is not a regulatory standard. A research compound that shares a name with an approved drug is not that drug. For research material, quality has to be shown lot by lot through independent testing and a certificate of analysis.

References

1. Ramzy, A., Asadi, A., & Kieffer, T. J. (2020). Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (PC) 1/3 but not PC2. Diabetes, 69(7), 1451. https://diabetesjournals.org/diabetes/article/69/7/1451/39562/Revisiting-Proinsulin-Processing-Evidence-That
2. Süssmuth, R. D., & Mainz, A. (2017). Nonribosomal Peptide Synthesis—Principles and Prospects. Angewandte Chemie International Edition, 56(14), 3770–3821. doi:10.1002/anie.201609079; PMID 28323366
3. Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402–7405. doi:10.1016/S0021-9258(18)42531-8; PMID 1313797
4. The Nobel Prize in Physiology or Medicine 1923 — Frederick Grant Banting and John James Rickard Macleod, “for the discovery of insulin.” NobelPrize.org. https://www.nobelprize.org/prizes/medicine/1923/summary/
5. Goeddel, D. V., Kleid, D. G., Bolivar, F., Heyneker, H. L., et al. (1979). Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceedings of the National Academy of Sciences USA, 76(1), 106–110. doi:10.1073/pnas.76.1.106
6. Smithsonian National Museum of American History. Recombinant Drugs (Birth of Biotech collection). https://americanhistory.si.edu/collections/object-groups/birth-of-biotech/recombinant-drugs
7. Merrifield, R. B. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society, 85(14), 2149–2154. doi:10.1021/ja00897a025
8. Woodcock, J. (30 October 2019). Safeguarding Pharmaceutical Supply Chains in a Global Economy. Congressional testimony of the Director, Center for Drug Evaluation and Research. U.S. Food and Drug Administration. https://www.fda.gov/news-events/congressional-testimony/safeguarding-pharmaceutical-supply-chains-global-economy-10302019
9. Bachem. About us (company overview and site locations). https://www.bachem.com/about-us/
10. CordenPharma (5 March 2025). CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland. https://cordenpharma.com/articles/press-release-cordenpharma-expands-peptide-platform-with-more-than-500-million-euro-greenfield-facility-construction-near-basel-switzerland/
11. PolyPeptide Group. Manufacturing sites. https://www.polypeptide.com/contacts/manufacturing-sites/
12. CordenPharma (6 September 2023). CordenPharma inaugurates increased peptide production of largest worldwide SPPS manufacturing plant. https://cordenpharma.com/articles/cordenpharma-inaugurates-increased-peptide-production-of-largest-worldwide-spps-manufacturing-plant/
13. AmbioPharm. About us. https://www.ambiopharm.com/about-us/
14. WuXi AppTec (8 January 2024). WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site. PR Newswire. https://www.prnewswire.com/news-releases/wuxi-apptec-triples-peptide-manufacturing-capacity-and-launches-the-new-taixing-api-manufacturing-site-302028093.html
15. WuXi AppTec (23 March 2026). WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025. https://www.wuxiapptec.com/news/wuxi-news/ukp6jpdhyncifp8ovk4kv1z6
16. Hybio Pharmaceutical (January 2026). Hybio Pharmaceutical completes official NMPA registration of semaglutide API. https://www.hybio.com/news/good-news-hybio-pharmaceutical-completes-official-nmpa-registration-of-semaglutide-api/
17. PolyPeptide Group (24 October 2025). Capacity expansion underway at our Ambernath facility. https://www.polypeptide.com/news/capacity-expansion-underway-at-our-ambernath-facility/
18. Fierce Pharma (20 March 2026). With Novo’s semaglutide going off patent, Indian drugmakers set to launch their cheaper generics. https://www.fiercepharma.com/pharma/novos-semaglutide-losing-patent-protection-indian-drugmakers-set-launch-their-generics
19. Eli Lilly and Company (24 May 2024). Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines. PR Newswire. https://www.prnewswire.com/news-releases/lilly-increases-manufacturing-investment-to-9-billion-at-newest-indiana-site-to-boost-api-production-for-tirzepatide-and-pipeline-medicines-302155135.html
20. GenScript (18 May 2023). GenScript Expands Peptide and Oligonucleotide Production Facility in China. PR Newswire. https://www.prnewswire.com/news-releases/genscript-expands-peptide-and-oligonucleotide-production-facility-in-china-301828241.html
21. The Week (14 April 2026). The regulation issues with grey-market peptides (reporting New York Times analysis of US customs data). https://theweek.com/health/peptides-injectables-grey-market-synthetic-wellness
22. Harmonized System heading 2937 and subheading 2937.19: hormones, prostaglandins, thromboxanes and leukotrienes, including chain modified polypeptides, used primarily as hormones. Tariffnumber.com. https://www.tariffnumber.com/2024/293719
23. Turnock, L. A., Hearne, E., & Lazuras, L. (2025). Made in China: The international supply of illicit Semaglutide and weight-loss medicines online. Emerging Trends in Drugs, Addictions, and Health, 5, 100169. doi:10.1016/j.etdah.2024.100169
24. U.S. Food and Drug Administration / ICH (September 2016). Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry
25. U.S. Food and Drug Administration (5 September 2025). FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients. https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients
26. Eli Lilly and Company (23 September 2025). Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas. https://investor.lilly.com/news-releases/news-release-details/lilly-plans-build-new-65-billion-facility-manufacture-active
27. Eli Lilly and Company (9 December 2025). Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama. https://investor.lilly.com/news-releases/news-release-details/lilly-build-6-billion-facility-manufacture-active-pharmaceutical
28. Catalent (18 December 2024). Novo Holdings Completes Acquisition of Catalent. https://www.catalent.com/news/novo-holdings-completes-acquisition-of-catalent
29. Electronic Code of Federal Regulations. 16 CFR Part 323 — Made in USA Labeling. https://www.ecfr.gov/current/title-16/chapter-I/subchapter-C/part-323

For more on the questions this guide touches, see How Peptides Are Made for the manufacturing chemistry, Understanding Peptide COA Testing for what a certificate of analysis does and does not prove, How to Buy Research Peptides for evaluating a supplier, What Are Peptides? for the basics, and Peptide vs Drug vs Biologic for the regulatory categories.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes where peptides are made in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the synthesis or manufacturing location of any specific product.